Identity
- Security key
- 17186
- Ticker
- IPHA
- Type
- ADRC — American Depository Receipt Common
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2015-09-09
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- IPHA
Detail
Enriched 2026-08-14 20:47
- Market cap
- $231,941,121.36
- Shares outstanding (class)
- 93,921,863
- Shares outstanding (weighted)
- 93,903,288
- SIC
- —
- Employees
- 163
- Location
- —
- Homepage
- https://www.innate-pharma.com
- Description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.